APA 6th Edition Reiner, Ž., Muačević-Katanec, D., Katanec, D. i Tedeschi-Reiner, E. (2011). SNIŽENI HDL-KOLESTEROL – VAŽAN ČIMBENIK RIZIKA OD KARDIOVASKULARNIH BOLESTI. Liječnički vjesnik, 133 (3-4), 0-0. Preuzeto s https://hrcak.srce.hr/171666
MLA 8th Edition Reiner, Željko, et al. "SNIŽENI HDL-KOLESTEROL – VAŽAN ČIMBENIK RIZIKA OD KARDIOVASKULARNIH BOLESTI." Liječnički vjesnik, vol. 133, br. 3-4, 2011, str. 0-0. https://hrcak.srce.hr/171666. Citirano 21.02.2020.
Chicago 17th Edition Reiner, Željko, Diana Muačević-Katanec, Davor Katanec i Eugenia Tedeschi-Reiner. "SNIŽENI HDL-KOLESTEROL – VAŽAN ČIMBENIK RIZIKA OD KARDIOVASKULARNIH BOLESTI." Liječnički vjesnik 133, br. 3-4 (2011): 0-0. https://hrcak.srce.hr/171666
Harvard Reiner, Ž., et al. (2011). 'SNIŽENI HDL-KOLESTEROL – VAŽAN ČIMBENIK RIZIKA OD KARDIOVASKULARNIH BOLESTI', Liječnički vjesnik, 133(3-4), str. 0-0. Preuzeto s: https://hrcak.srce.hr/171666 (Datum pristupa: 21.02.2020.)
Vancouver Reiner Ž, Muačević-Katanec D, Katanec D, Tedeschi-Reiner E. SNIŽENI HDL-KOLESTEROL – VAŽAN ČIMBENIK RIZIKA OD KARDIOVASKULARNIH BOLESTI. Liječnički vjesnik [Internet]. 2011 [pristupljeno 21.02.2020.];133(3-4):0-0. Dostupno na: https://hrcak.srce.hr/171666
IEEE Ž. Reiner, D. Muačević-Katanec, D. Katanec i E. Tedeschi-Reiner, "SNIŽENI HDL-KOLESTEROL – VAŽAN ČIMBENIK RIZIKA OD KARDIOVASKULARNIH BOLESTI", Liječnički vjesnik, vol.133, br. 3-4, str. 0-0, 2011. [Online]. Dostupno na: https://hrcak.srce.hr/171666. [Citirano: 21.02.2020.]
Sažetak It has been known for quite a long time that the concentration of HDL-cholesterol correlates inversely with cardiovascular disease (CVD) risk and that low HDL-cholesterol is an independent CVD risk factor. This review aims to highlight evidence on several topics concerning the role of HDL particles and the importance of HDL-cholesterol. The main antiatherogenic functions of HDL particles are presented in details – reverse cholesterol transport, but also their anti-oxidant, anti-inflammatory, anti-thrombotic and anti-apoptotic properties as well as endothelial stabilizing and repair properties. Lifestyle management of low HDL-cholesterol is explained, particularly physical activity and aerobic exercise, smoking cessation, weight reduction in the overweight individuals and composition of the diet but also moderate alcohol consumption stressing the fact that HDL particles from alcoholics are dysfunctional. This is important since it has been shown that it is not only the quantity of HDL particles, and thus HDL-cholesterol level in plasma, that matters, but their quality and impaired functionality as well. HDL from diabetic subjects also lose some of their antiatherogenic properties but a common feature of patients with diabetes type 2 is atherogenic dyslipidemia which is characterized exactly by low HDL-cholesterol and high triglycerides. Diabetic patients with such dyslipidemia are at particularly high CVD risk and the results of recent studies such as ACCORD-Lipid suggest that in them treatment of these lipid abnormalities may be beneficial. Treatment options with fibrates, particularly fenofibrate, and niacin are discussed based upon published trials, as well as combination therapy with these medicines and other lipid-lowering drugs.